

For Internal Use Only		Submit 1 Original		OMB Approval No.:
Sec File No. 91 -		and 9 Copies		Expires:

Estimated average burden hours per response: 2.00

91-1620

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 19b-4(e)**

**Information Required of a Self-Regulatory Organization Listing and Trading a New  
Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934**

**READ ALL INSTRUCTIONS PRIOR TO COMPLETING FORM**

**Part I Initial Listing Report** SECURITIES AND EXCHANGE COMMISSION

1. Name of Self-Regulatory Organization Listing New Derivative Securities Product:  
NYSE Area, Inc. APR 20 2007

2. Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.):  
Open-end Management Investment Company DIVISION OF MARKET REGULATION

3. Class of New Derivative Securities Product:  
Investment Company Units

4. Name of Underlying Instrument:  
HealthShares™ Dermatology and Wound Care Index



5. If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow-Based:  
Narrow-Based

6. Ticker Symbol(s) of New Derivative Securities Product:  
HRW

7. Market or Markets Upon Which Securities Comprising Underlying Instrument Trades:  
New York Stock Exchange, Nasdaq Stock Market, Oslo Bors (Oslo Stock Exchange), SWX Swiss Exchange, London Stock Exchange, Euronext Brussels, Xetra

**PROCESSED**

8. Settlement Methodology of New Derivative Securities Product:  
Regular way trades settle on T+3/Book entry only held in DTC. MAY 08 2007

9. Position Limits of New Derivative Securities Product (if applicable):  
Not applicable. J THOMSON FINANCIAL

**Part II Execution**

The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.

Name of Official Responsible for Form:  
Mary Yeager

Title:  
Corporate Secretary

Telephone Number:  
(212) 656-2062

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability:	APR 20 2007

Manual Signature of Official Responsible for Form:  
*Mary Yeager*  
April 19, 2007

Mary Yeager  
Corporate Secretary

NYSE Arca, Inc.  
11 Wall Street  
New York, NY 10005



tel: 212.656.2062  
fax: 212.656.3939  
myeager@nyse.com

Via Overnight Mail

April 19, 2007

SECURITIES AND EXCHANGE COMMISSION

RECEIVED

APR 20 2007

DIVISION OF MARKET REGULATION

Ms. Gail Jackson  
US Securities and Exchange Commission  
Division of Market Regulation  
Station Place – Building I  
100 F Street, N.E. – Room 6628  
Washington, DC 20549

Re: Form 19b-4(e) – HealthShares<sup>TM</sup>, Inc.

Dear Ms. Jackson:

Enclosed for filing pursuant to Section 19(b) of the Securities Exchange Act of 1934 and Rule 19b-4 thereunder, please find an original and nine copies of Form 19b-4(e) with respect to the following security:

- HealthShares, Inc., HealthShares<sup>TM</sup> Dermatology and Wound Care Exchange-Traded Fund (Ticker Symbol HRW).

If you have any questions, please do not hesitate to call me at (212) 656-2062.

Sincerely,

Enclosures

Cc: Tim Malinowski (NYSE Arca, Inc.)

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability:	APR 20 2007

END